Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet.

Liang XuNaoto NagataGuanliang ChenMayumi NagashimadaFen ZhugeYinhua NiYuriko SakaiShuichi KanekoTsuguhito Ota

Published in: BMJ open diabetes research & care (2019)

Treatment with empagliflozin attenuated weight gain by increasing energy expenditure and adipose tissue browning, and alleviated obesity-associated inflammation and insulin resistance by alternative macrophage activation in the WAT and liver of obese mice.

Keyphrases

insulin resistance
adipose tissue
high fat diet induced
high fat diet
weight gain
body mass index
polycystic ovary syndrome
birth weight
oxidative stress
metabolic syndrome
weight loss
skeletal muscle
type diabetes
glycemic control
replacement therapy
preterm birth